Analyst Ratings For NASDAQ:BTAI – BioXcel Therapeutics (NASDAQ:BTAI)
Today, HC Wainwright reiterated its Buy rating on NASDAQ:BTAI – BioXcel Therapeutics (NASDAQ:BTAI) with a price target of $25.00.
Some recent analyst ratings include
- 6/12/2018-HC Wainwright Reiterated Rating of Buy.
- 4/2/2018-Canaccord Genuity initiated coverage with a Buy rating.
- 4/2/2018-BMO Capital Markets initiated coverage with a Outperform rating.
- 4/2/2018-UBS Group initiated coverage with a Buy rating.
- 4/2/2018-Barclays initiated coverage with a Overweight ➝ Overweight rating.
Recent Trading Activity for NASDAQ:BTAI – BioXcel Therapeutics (NASDAQ:BTAI)
Shares of NASDAQ:BTAI – BioXcel Therapeutics closed the previous trading session at 10.34 down -0.39 3.59% with 10.3100004196167 shares trading hands.